Podcasts about GU

En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=4SvBCboznFg ¿Qué ocurre cuando una mujer reconecta con su energía creativa, su cuerpo y su propósito? Aquí exploramos cómo activar la energía femenina para vivir con abundancia. Hablamos de merecimiento, liderazgo interior y del despertar de la mujer soberana que ya habita en ti. Abundancia, dones y propósito Emprender desde el alma La diosa que despierta en cada mujer Una charla profunda para mujeres que desean vivirse libres, completas y luminosas. Florencia Bas Mentora de negocios energéticos. Guía a mujeres a activar su energía matriz y vital, reconectar con sus dones y crear negocios conscientes, impactando con propósito en las 5 áreas de una vida millonaria. https://florbas.tiendup.com/ / florbas.canal #Abundancia #EnergíaFemenina #CrecimientoPersonal Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. -----------INFORMACIÓN SOBRE MINDALIA--------- Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.

Este es el episodio #116 de “Tradiciones Sabias”, el podcast en español de la Fundación Weston A. Price. Algunos de los temas de este episodio - Diferencias en las bases de la Agricultura Orgánica y la Agricultura Industrial Cómo ha ido creciendo el interés de las multinacionales en la Agricultura Orgánica  Cómo la Agricultura Orgánica utiliza la magia de las fermentaciones y el Sol Cuáles con las nuevas regulaciones para la Agricultura Orgánica por las Naciones Unidas y el Banco Mundial Cifras impactantes sobre la producción de alimentos a nivel mundial que contradicen las campañas que tratan de convencernos de que no se produce suficiente alimento para el mundo Datos del invitado - Jairo Restrepo Rivera nació en Colombia y se naturalizó en Brasil. Es ingeniero agrónomo y conferencista a nivel mundial con 45 años de experiencia en agricultura orgánica. Ha sido consultor en prácticamente toda América y varios países de África, Europa y Australia. Ha ofrecido cientos de conferencias, cursos y talleres  en más de 30 países a estudiantes, campesinos y profesionales y es autor de más de 10 libros y un sinnúmero de artículos. Contacto - Instagram: https://www.instagram.com/lamierdadevaca/ YouTube: https://www.youtube.com/playlist?list=PLg1y1OogHCW6mwtXpx16gtnzjULENxtWR Página web: https://lamierdadevaca.com Preguntas, comentarios, sugerencias - tradicionessabias@gmail.com     Recursos en español de la Fundación Weston A. Price -   Página web WAPF en Español: https://www.westonaprice.org/espanol/ Cuenta de Instagram: westonaprice_espanol Guía alimentación altamente nutritiva, saludable y placentera: 11 principios dietéticos Paquete de Materiales GRATIS: https://secure.westonaprice.org/CVWEBTEST_WESTON/cgi-bin/memberdll.dll/openpage?wrp=customer_new_infopak_es.htm  Folleto "La Leche Real", de Sally Fallon:  https://www.westonaprice.org/wp-content/uploads/La-leche-real.pdf  Música de Pixabay - Sound Gallery y SOFRA  

En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=wRMaTEnHgTI Las Constelaciones no solo revelan datos del código familiar, sino también de la esencia profunda del Ser: vidas pasadas, energía presente y conexión mente-corazón-alma. Gracias a las cartas energéticas, Sonia recibe una "radiografía" de la persona, brindándole así mayor seguridad para confiar en su intuición y su camino. Sonia Talabante Terapeuta Humanista (Gestalt, Guía de Constelaciones Familiares entre otros). Educadora social, fundadora y codirectora de un centro de crecimiento personal. https://retrobat.cat/ / sonia.talabante / soniatalabante Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. ------------INFORMACIÓN SOBRE MINDALIA----------DPM Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.

In this episode, the Ljósvetnings and Möðruvellings maneuver to position themselves to maximize potential outcomes in the aftermath of the battle of Battle Hill. While Þorvarður Höskuldsson does his best to calm tensions and shield his allies, Eyjólfur Guðmundarson wants more than financial compensation for the killing of his "beloved" brother Koðrán. And just like last time, both sides rally supporters from far and wide, each determined to force the results that benefit them most. As the thing draws near, the risk of open violence continues to loom large. And when everyone arrives, there's a very real chance that Eyjólfur will get the bloody revenge he's been thirsting after, even if it means dooming many of his own men in the process. Quick note: In the episode, I think we say this meeting takes place at the Althing. I'm convinced (this is Andy here) that the conflict takes place at the local thing in the north and not at the Althing. These few chapters capture the tensions and drama that we love most in the sagas: carefully laid legal strategies, preparations for battle, and the ever-present threat that everything is about to pop off in spectacular fashion. Will everything resolve with a fair and equitable legal resolution? Or will Eyjólf water the grounds of the thing site with the blood of his enemies (and his companions)? There's only one way to find out! Listen and let us know what you think: Sagathingpodcast on Facebook Sagathingpodcast on Instagram Sagathingpodcast on Bluesky Saga Thing's unofficial official Discord Music Credits Intro Music - "Prelude and Action" by Kevin MacLeod Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ Outro Music - "Stormfront" by Kevin MacLeod Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/

Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.

¿Por qué repetir afirmaciones no funciona? Porque tu subconsciente no escucha lo que dices… siente lo que sientes. En este video te revelo un método olvidado, silenciado por la medicina formal y redescubierto por la neurociencia moderna. Un método simple, efectivo y profundamente transformador que puedes aplicar cada mañana entre las 4:00 y las 6:00 a.m. Aprende a reprogramar tu mente desde el cuerpo, no desde el intelecto. Aplícalo durante 7 días y comparte en los comentarios qué descubriste. Explora más herramientas de transformación en: Guías y recursos: https://conocimientoexperto.com/accede-a-las-guias Podcast Oficial: https://open.spotify.com/show/65J8RTsruRXBxeQElVmU0b Instagram: https://www.instagram.com/salvadormingo/ Comparte este contenido con quien busca algo más que motivación momentánea. ✒ Salvador Mingo Creador de Conocimiento Experto #ReprogramaTuMente #Subconsciente #Autosugestión #DesarrolloPersonalReal #SalvadorMingo #ConocimientoExperto #Neuroplasticidad #4AMMindset

Ísland er úr leik á Evrópumótinu eftir tvö töp í tveimur leikjum. Við eigum ekki lengur möguleika á því að komast áfram sem er gífurlega sárt. Vonbrigðin leyndu sér ekki hjá leikmönnum, starfsfólki og stuðningsmönnum Íslands í gær enda voru markmiðin stærri en þetta. Ísland er úr leik þegar einn leikur er eftir í riðlinum og er hægt að segja að maður finni fyrir ákveðinni tómleikatilfinningu út af þessum vonbrigðum. Undirritaður, Guðmundur Aðalsteinn, settist niður með Eddu Sif og Einari Erni frá RÚV í Thun í dag og gerði upp vonbrigðin.

¿Por qué repetir afirmaciones no funciona? Porque tu subconsciente no escucha lo que dices… siente lo que sientes. En este video te revelo un método olvidado, silenciado por la medicina formal y redescubierto por la neurociencia moderna. Un método simple, efectivo y profundamente transformador que puedes aplicar cada mañana entre las 4:00 y las 6:00 a.m. Aprende a reprogramar tu mente desde el cuerpo, no desde el intelecto. Aplícalo durante 7 días y comparte en los comentarios qué descubriste. Explora más herramientas de transformación en: Guías y recursos: https://conocimientoexperto.com/accede-a-las-guias Podcast Oficial: https://open.spotify.com/show/65J8RTsruRXBxeQElVmU0b Instagram: https://www.instagram.com/salvadormingo/ Comparte este contenido con quien busca algo más que motivación momentánea. ✒ Salvador Mingo Creador de Conocimiento Experto #ReprogramaTuMente #Subconsciente #Autosugestión #DesarrolloPersonalReal #SalvadorMingo #ConocimientoExperto #Neuroplasticidad #4AMMindsetConviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/conocimiento-experto--2975003/support.

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

From painless hematuria to paraneoplastic syndromes, GU cancers can get overwhelming very quickly. Fortunately, OMS3 Angelica Batholomew from Ohio University Heritage College of Osteopathic Medicine in Cleveland will make this topic much easier!

En Ivoox puedes encontrar sólo algunos de los audios de Mindalia. Para escuchar las 4 grabaciones diarias que publicamos entra en https://www.mindaliatelevision.com. Si deseas ver el vídeo perteneciente a este audio, pincha aquí: https://www.youtube.com/watch?v=fTYjSMnfrbU Nuestra biología tiene una tecnología muy avanzada que se está relacionando con la realidad digital actual, capta señales y las descodifica para acceder a un mayor potencial. Grisy Nava te guía para hacerte consciente de esta tecnología y aprovechar todo su poder a tu favor. Grisy Nava Entrenadora espiritual y conferencista internacional con más de 10 años de experiencia. Se enfoca principalmente en el desarrollo de la conciencia y ofrece seminarios y cursos para este fin, siempre con la orientación de sus Guías. Más información en: https://www.mindalia.com/television/ PARTICIPA CON TUS COMENTARIOS EN ESTE VÍDEO. -----------INFORMACIÓN SOBRE MINDALIA--------- Mindalia.com es una ONG internacional, sin ánimo de lucro, que difunde universalmente contenidos sobre espiritualidad y bienestar para la mejora de la consciencia del mundo. Apóyanos con tu donación en: https://www.mindalia.com/donar/ Suscríbete, comenta positivamente y comparte nuestros vídeos para difundir este conocimiento a miles de personas. Nuestro sitio web: https://www.mindalia.com SÍGUENOS TAMBIÉN EN NUESTRAS PLATAFORMAS Facebook: / mindalia.ayuda Instagram: / mindalia_com Twitch: / mindaliacom Odysee: https://odysee.com/@Mindalia.com *Mindalia.com no se hace responsable de las opiniones vertidas en este vídeo, ni necesariamente participa de ellas.

Ísland fékk ekkert úr úr leiknum sínum gegn Finnlandi í fyrsta leik Evrópumótsins í gær. Niðurstaðan var 1-0 sigur Finnland. Frammistaða Íslands var ekki góð í leiknum og sérstaklega var það raunin í fyrri hálfleik. Það virtist vera mikið stress í liðinu. Guðmundur Aðalsteinn settist niður með Aroni Guðmundssyni hjá Sýn og Helga Fannari Sigurðssyni, fréttamanni 433, í dag og var leikurinn gerður upp.

Abogada Evelyn de Guély

In this special Saga Brief, we wrap up our four-part series from Iceland with an interview recorded in the shadow of Snæfellsjökull, one of the most iconic landscapes in the country. This time, we are joined by Ragnhildur Sigurðardóttir, park manager of Snæfellsjökull National Park, for a wide-ranging conversation about the sagas, Icelandic heritage, and the powerful connection between people and place. Snæfellsjökull National Park is a natural treasure of Iceland and a must-see destination for fans of Saga Thing and lovers of history, literature, and nature alike. Located at the western tip of the Snæfellsnes Peninsula, it was established to protect the dramatic landscapes surrounding the iconic peak of the glacier-capped volcano Snæfellsjökull. The park encompasses a remarkable variety of geological features, from windswept lava fields and jagged cliffs to hidden caves and mossy craters. It's a place where history, legend, and natural beauty intertwine seamlessly. After a full day of work in the park, Ragnhildur met us in nearby Arnarstapi at the foot of the massive statue of Bárður Snæfellsás. You may remember Bárður as the mythical guardian of the peninsula and central figure in Bárðar saga Snæfellsáss. As a self-described book lover and lifelong reader of the sagas, Ragnhildur brought a deeply personal perspective to our conversation, especially in her reflections on Guðríður víðförla Þorbjarnardóttir (Gudrid the Far-Traveled) from the Vinland sagas. As we mention in the intro, this interview came at the end of an unforgettable day that included a magical horse ride along the beach with Siggi from Stóri-Kambur and several stops at saga sites. It was the kind of day where the sagas feel alive in the landscape, which was one of the most important goals of this trip. And, if you're planning a trip to the Snæfellsnes peninsula, we highly recommend a stop at Stóri-Kambur, where you can ride one of their beautiful Icelandic horses and learn about the special place these animals hold in Icelandic culture and daily life. We're so grateful to Ragnhildur for sharing her time and insight with us. Her deep care for the land and its stories really shines through in this conversation. Enjoy the episode and then let us know what you think on our social media: Sagathingpodcast on Facebook Sagathingpodcast on Instagram Sagathingpodcast on Bluesky Saga Thing's unofficial official Discord Music Credits: Opening song – “Rúnatal” by An Danzza Introduction – from Icelandic Folk Music: Tröllaslagur Outro – Ólafur Liljurós  

Este es el episodio #115 de “Tradiciones Sabias”, el podcast en español de la Fundación Weston A. Price. Algunos de los temas de este episodio: - Diferencias entre la crianza de cerdos nativos o criollos de México y los cerdos de modelos industriales o de confinamiento - Cómo aplican el modelo de silvopastoreo con sus cerdos y cuáles son los beneficios de este modelo - Cómo es la dieta variedad de los cerdos que crían - Por qué los cerdos son bajos en PUFA y cómo es el perfil de sus grasas Datos Biográficos: David Lynch nació en Salem, Massachusetts, Estados Unidos y vive en México desde el año 2009.  Estudió la licenciatura en Bioquímica y Biología Celular en Rice University y, junto a su esposa, fundaron Rancho El Risueño en el año 2017, en donde crían cerdos y reses criollas con un modelo al cual le llaman pastoreo megadiverso en el Bosque Seco Tropical de Jalcomulco en el estado de Veracruz. Contacto: - Instagram/Rancho El Risueño Preguntas, comentarios, sugerencias: tradicionessabias@gmail.com      Recursos en español de la Fundación Weston A. Price -   - Página web WAPF en Español: https://www.westonaprice.org/espanol/ - Cuenta de Instagram: westonaprice_espanol - Guía alimentación altamente nutritiva, saludable y placentera:  11 principios dietéticos - Paquete de Materiales GRATIS:  https://secure.westonaprice.org/CVWEBTEST_WESTON/cgi-bin/memberdll.dll/openpage?wrp=customer_new_infopak_es.htm  - Folleto "La Leche Real", de Sally Fallon:  https://www.westonaprice.org/wp-content/uploads/La-leche-real.pdf  Música de Pixabay: Sound Gallery y SOFRA

¿Eres emprendedora, creadora de contenido o coach y estás lista para tomar  imperfecta acción con tu negocio digital? ¡Este espacio es para ti! 

Ýmsir þættir hafa áhrif á hvar við ákveðum að búa til lengdar og hversu vel okkur líður í heimahögunum. Nýleg rannsókn sýnir til að mynda að einstaklingar sem búsettir eru í fáumennum byggðarlögum hérlendis og upplifa slúður um sitt ástarlíf eru tvöfalt líklegri til þess að ætla að flytjast búferlum en aðrir sem ekki upplifa slíkt. Til að færa okkur í allan sannleika um áhrif slúðurs á búsetu og búsetuánægju og margt fleira er í þessum þætti rætt við Dr. Grétu Bergrúnu Jóhannesdóttur sérfræðing við Rannsóknasetur byggða- og sveitarstjórnarmála við Háskólann á Bifröst. Gréta lauk doktorsgráðu í félagsfræði frá Háskólanum á Akureyri á síðasta ári en titill ritgerðarinnar er „Ein af þessum sögum: Félagslegt taumhald, fólksflutningar og slúður: ungar konur í litlum byggðarlögum á Íslandi.“ Guðmundur Oddsson prófessor í félagsfræði við HA ræddi við Grétu en í spjalli þeirra kennir ýmissa grasa.

From painless hematuria to paraneoplastic syndromes, GU cancers can get overwhelming very quickly. Fortunately, OMS3 Angelica Batholomew from Ohio University Heritage College of Osteopathic Medicine in Cleveland will make this topic much easier!

"You've cultivated enough self trust and you know what you're doing, now can you listen to your body? Can you listen to your horse? Even if it doesn't look like what somebody else is saying is good or bad or right or wrong, how can you own that for you and not get swept up in this huge amount of what other people are doing." - Felicity  Connect with me at: https://www.felicitydavies.com.au https://www.instagram.com/felicitydavies_/ https://www.felicitydavies.com.au/offerings   Connect with Güliz at:  https://www.equuarius.com/ https://www.instagram.com/equuarius/ and listen to her on Season 2 Episode 17 of the Equestrian Perspective Podcast - https://open.spotify.com/show/54Jn0lR1sA5vqNv5lIiDve    

Íslenska kvennalandsliðið hefur á morgun leik á Evrópumótinu er þær spila við Finnland í fyrsta leik. Guðmundur Aðalsteinn er staddur í Thun í Sviss þar sem hann er að fjalla um liðið. Hann settist niður í kvöld með þeim Bjarna Helgasyni og Ágústi Beinteini, betur þekktum sem Gústa B, af Morgunblaðinu. Ræddu þeir um fyrstu dagana í Thun, leikinn á morgun og möguleika Íslands.

SWING MASTER | CURSO EN VIVO | 01 AL 04 DE JULIONo te lo pierdas! Mas info Aquí!

Útvarpsþátturinn Fótbolti.net á X977 laugardaginn 28. júní. Umsjón: Elvar Geir og Valur Gunnars. Besta deildin er í aðalhlutverki og leikir gærdagsins gerðir upp. Lárus Orri Sigurðsson, nýr þjálfari ÍA, er á línunni og Tryggvi Guðmunds skoðar komandi leiki. Lengjudeildin er á sínum stað og Guðmundur Aðalsteinn er í beinni frá Sviss þar sem EM kvenna fer í gang á miðvikudag.

https://solvitryggva.is/ Guðmundur Ebenezer Birgisson er reyndur sálfræðingur með háskólagráður í 3 greinum, sem sagði upp vel launuðu starfi í Noregi til að elta drauminn og byrja með fyrirtæki sem þróar lausnir í geðheilsu í gegnum internetið. Guðmundur og Sölvi ræða hér mikilvægi þess að þora að elta draumana og setja sér háleit markmið. Þeir fara í þættinum yfir þróun sálfræði og geðheilsu og hvaða lausnir gætu nýst best á komandi árum til að bæta vellíðan og geðheilsu fólks. Þátturinn er í boði; Caveman - https://www.caveman.global/ Nings - https://nings.is/ Myntkaup - https://myntkaup.is/ Biofit - https://biofit.is/ Exoquad - https://www.exoquad.is

Styrktaraðilar þáttarins eru: Myntkaup, World Class, Silkisvefn, Gæði, Takk takk (SB15 fyrir 15% afslátt á takktakk.is)www.patreon.com/skodanabraedurÍ fyrri hlutanum af samtalinu okkar við Kjartan Þórisson frumkvöðul förum við djúpt í það hvernig maður hámarkar sína eigin getu, orku og lífskraft. Við ræðum mikilvægi þess að lifa í fullum heilindum, hvaða venjur styrkja okkur og hvernig á að gera þetta allt saman. Í seinni hlutanum verða hlutirnir teknir fyrir á macro-skala. Guð blessi ykkur kæra bræðralag.

Australia has a dark chapter of history that many are still learning about. Following European settlement, Aboriginal and Torres Strait Islander children were removed from their families and forced into non-Indigenous society. The trauma and abuse they experienced left deep scars, and the pain still echoes through the generations. But communities are creating positive change. Today these people are recognised as survivors of the Stolen Generations. - Australia aleŋ anyiköl alɔŋ cool ŋuɔ̈t piöc kɔc kɔ̈k bïk ŋic. Buɔ̈th bɛn kɔc tuëŋ European ci ke ciök riëk piny, mith Aboriginal and Torres Strait Islander aci nyiäi kääcken cïn ku thɛ̈ɛ̈ny kek muök kɔc cie-Aboriginal akutnhom dɛt. Guöm ku yioŋyiöŋ ci reet ke nhiim aci keek nyiäŋ ke piɛ̈ɛ̈r ke guop, ku arɛɛm a ŋuɔt latuëŋ riëëny kith yiic. mɛ̈n wuönken aci ke pɛth looi bïk näŋ ke pɛɛth waar kë. Yekölë, kɔc käk aŋic kek ke piir ke ye kɔc e rïïny cï kuäl wei.

Hoy es 27 de junio, Día de las Víctimas del Terrorismo en España. Se eligió esta fecha porque hoy, hace 65 años, una bomba mató a la niña de 20 meses Begoña Urroz. Fue en la estación de tren de Amara, en Donosti. La pérdida fue tan fuerte para la familia que cuando años después nació otra niña, le pusieron el mismo nombre. Y esa es la verdadera protagonista de esta historia: Begoña Urroz Esta es la historia que Isabel Cadenas Cañón cuenta a Begoña Urroz en la tercera temporada del podcast ‘De eso no se habla’: Se llamaba como yo. Hablamos con la propia Isabel para que nos explique los detalles de su investigación, para poner en orden todos estos silencios individuales que cuentan mucho sobre nuestros silencios colectivos. *** Si te interesa, puedes escuchar la serie completa de ‘Se llamaba como yo’ *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Aujourd'hui, je vous propose un épisode spécial burnout du podcast Pourquoi pas moi.J'ai eu la chance d'interviewer le Dr Marine Crest, médecin généraliste, psychologue, spécialiste du microbiote… et surtout profondément engagée sur le sujet du burn-out. Marine parle en connaissance de cause : elle a elle-même traversé cette épreuve.Cet échange précieux a été initialement offert en exclusivité aux membres de mon programme "Rebondir après un burnout", et nous avons décidé, avec Marine, de le rendre accessible à toutes et tous.Dans cet épisode, elle nous éclaire avec bienveillance et expertise sur :ce qui peut mener à un burn-out,quand et comment se remettre en mouvement,quoi faire dès les premières semaines d'arrêt,comment l'entourage peut soutenir au mieux,les outils pour éviter la rechute,et bien plus encore.Elle nous parle aussi de son association Guérir en mer, née de son propre parcours. Que tu sois en plein burn-out, ou simplement concerné.e de près ou de loin, cet épisode est une mine d'or.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Lorsqu'elle a reçu les clés de son logement, un poids est tombé des épaules d'Angelika Stibi. Cette retraitée allemande dans le besoin ne paiera plus que 88 cents de loyer par mois, dans le plus vieil habitat social du monde,en Bavière.La sexagénaire fait partie depuis le printemps des quelque 150 habitants de la "Fuggerei", une résidence d'Augsbourg, dans le sud de l'Allemagne, dont le loyer n'a pas bougé ... depuis le Moyen-Age.Créés en 1521 par le banquier Jacob Fugger, les plus vieux logements sociaux du monde, selon leurs administrateurs, sont toujours en service et très demandés.Réalisation : Emmanuelle BaillonReportage AFPTV : Olivier FenietDoublages : Camille Buonanno, Emmanuelle Michel, Michaëla Cancela-Kieffer, Sofiane Ouanes, Meïssa Guèye, Luca MatteucciSur le Fil est le podcast quotidien de l'AFP. Vous avez des commentaires ? Ecrivez-nous à podcast@afp.com. Vous pouvez aussi nous envoyer une note vocale par Whatsapp au + 33 6 79 77 38 45. Si vous aimez, abonnez-vous, parlez de nous autour de vous et laissez-nous plein d'étoiles sur votre plateforme de podcasts préférée pour mieux faire connaître notre programme Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

SWING MASTER | CURSO EN VIVO | 01 AL 04 DE JULIONo te lo pierdas! Mas info Aquí!

España tiene el mejor dato de paro en 17 años: eso nos lleva a 2008, a las cifras que había justo antes y después de la crisis económica. Tras una década de locura política y una pandemia después, con un cierto cambio de filosofía en la política económica de Europa y con un gobierno de coalición de izquierdas, hoy hay mejores datos de empleo. Más gente trabajando: hay más afiliados a la Seguridad Social que nunca. En este episodio hemos querido analizar cómo ha cambiado desde 2008 el mercado de trabajo en España y comprender que no todo es bueno aunque los grandes datos brillen de lejos. Lo hacemos con la periodista de elDiario.es especializada en asuntos laborales, Laura Olías. *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

Este es el episodio #114 de “Tradiciones Sabias”, el podcast en español de la Fundación Weston A. Price. Algunos de los temas de este episodio: - Por qué el ser humano es una especie clave para mantener ecosistemas - Qué otras especies juegan un rol clave - Cómo históricamente el ser humano ha mantenido ecosistemas diversos en todo el mundo - Técnicas y herramientas que hemos usado a través de los años Datos Biográficos: Raimundo es Científico de la Universidad Waikato, de Nueva Zelanda. Sus estudios son en Ciencias de la Tierra con Especialización en Suelos, Permacultura, Agricultura Sintrópica y Manejo Holístico. Se dedica a aplicar estos conocimientos en un ex terreno forestal altamente degradado, descubriendo a diario el gran potencial de la Restauración Agroecosistema, realizando Consultorías prediales a lo largo de todo Chile y el mundo. Contacto: - Web: www.yoregenero.org  - Instagram: instagram.com/yo_regenero  Preguntas, comentarios, sugerencias: tradicionessabias@gmail.com      Recursos en español de la Fundación Weston A. Price -   - Página web WAPF en Español: https://www.westonaprice.org/espanol/ - Cuenta de Instagram: westonaprice_espanol - Guía alimentación altamente nutritiva, saludable y placentera:  11 principios dietéticos - Paquete de Materiales GRATIS:  https://secure.westonaprice.org/CVWEBTEST_WESTON/cgi-bin/memberdll.dll/openpage?wrp=customer_new_infopak_es.htm  - Folleto "La Leche Real", de Sally Fallon:  https://www.westonaprice.org/wp-content/uploads/La-leche-real.pdf  Música de Pixabay: Sound Gallery y SOFRA  

¿Eres emprendedora, creadora de contenido o coach y estás lista para tomar  imperfecta acción con tu negocio digital? ¡Este espacio es para ti! 

Depuis le mois de décembre 2024, la Belgique permet aux travailleurs et travailleuses du sexe d'être salariés. C'est le premier pays au monde à donner accès à un tel droit aux personnes en situation de prostitution. Saluée par de nombreuses associations, cette nouvelle loi offre une protection et une sécurité inédite aux travailleurs et travailleuses du sexe en les consiérant comme des salariés comme les autres. Mais la mise en application de cette législation reste compliquée.Sur le fil vous emmène en Belgique, à la rencontre de ces nouveaux salariés avec, sur le terrain, Dimitri Korczak, journaliste reporter d'images à l'AFP.Invités : Thierry Schaffauser, trésorier du Syndicat du Travail Sexuel, en France"Mel", connue sous le pseudo de Meliciousss, travailleuse du sexe et militanteMarianne Chargois, travailleuse du sexe et militante pour l'Union des Travailleur·euses du Sexe, en BelgiqueCharles-Eric Clesse, magistrat belge expert en droit du travail et en matière de traite des êtres humainsCrédits TikTok : @weesliefvoorelkaarmetmel “Mel meliciousss”Réalisation : Camille BuonannoPrésentation : Emmanuelle BaillonDoublages : Meïssa Guèye Sur le Fil est le podcast quotidien de l'AFP. Vous avez des commentaires ? Ecrivez-nous à podcast@afp.com. Vous pouvez aussi nous envoyer une note vocale par Whatsapp au + 33 6 79 77 38 45. Si vous aimez, abonnez-vous, parlez de nous autour de vous et laissez-nous plein d'étoiles sur votre plateforme de podcasts préférée pour mieux faire connaître notre programme. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

En España hay más de 2.200 personas con títulos nobiliarios, distinciones otorgadas a lo largo de la historia por los diferentes reyes de España y que se heredan de padres a hijos. Desde este mes de junio hay seis personas más que entran en el club de la aristocracia por decisión de Felipe VI, que ha repartido títulos por primera vez: el tenista Rafa Nadal, la cantante Luz Casal, la nadadora paralímpica Teresa Fernández Perales, la fotógrafa Cristina García Rodero, el científico bioquímico Carlos López Otín y Jaime Alfonsín Alonso, ex jefe de la Casa Real, que será, él y sus sucesores, marqués de Alfonsín. Ninguno de estos títulos lleva aparejado la posesión de tierras ni privilegios fiscales, pero que en 2025 nombren a Rafa Nadal marqués Llevant de Mallorca o a Luz Casal marquesa de Luz y Paz suena entre cómico y decadente. Hablamos con Aitor Riveiro, periodista de elDiario.es que ha analizado este reparto de títulos para intentar entender qué mensaje político hay detrás de esta decisión. Con Alicia Rivas, profesora de Derecho Constitucional en la Universidad Pablo de Olavide, analizamos cómo encaja en nuestra democracia esto de distinguir a unas personas y a todos sus descendientes por encima de otras, aunque sea solo de forma simbólica. *** Envíanos una nota de voz por Whatsapp contándonos alguna historia que conozcas o algún sonido que tengas cerca y que te llame la atención. Lo importante es que sea algo que tenga que ver contigo. Guárdanos en la agenda como “Un tema Al día”. El número es el 699 518 743See omnystudio.com/listener for privacy information.

We head back in time to discuss the biggest pop culture moments and news from the year 2000!Mac kicks off the episode with the year's superlatives, before Gu breaks out the tiermaker and the gruesome twosome decide what is truly important from the year 2000!Join the conversation... FacebookInstagramTwitterTikTokYouTubeRate/Review/Subscribe:Apple PodcastsSpotifyYouTube

La nanotecnóloga y divulgadora Anna Morales nos habla sobre la ciencia detrás de ficciones como 'Guía del autoestopista galáctico'

La nanotecnóloga y divulgadora Anna Morales nos habla sobre la ciencia detrás de ficciones como 'Guía del autoestopista galáctico'

En este episodio vamos directos al grano: Guía paso a paso para ganar dinero en bolsa en 2025, sobre todo, en esta segunda mitad, ya que las cosas han cambiado un poco. Qué acciones comprar, por qué... Y mucho más.OFERTA DE VERANO: 15% de Descuento + Suites de formación: Con el código "VERANOBC" en: https://boringcapital.net/contrata

La nanotecnóloga y divulgadora Anna Morales nos habla sobre la ciencia detrás de ficciones como 'Guía del autoestopista galáctico'

La nanotecnóloga y divulgadora Anna Morales nos habla sobre la ciencia detrás de ficciones como 'Guía del autoestopista galáctico'

Grabamos un podcast a 4500 metros de altura, en la locación donde se filmó la película "El Páramo" en 2011.Segundo capítulo de la serie RODANDO POR EL EJE, donde visitamos algunas de las locaciones que hacen parte de la GUÍA DE TURISMO CINEMATOGRÁFICO desarrollada por el equipo de La Falla Destino Fílmico.Link de Youtube aquíEn este episodio salimos desde Santa Rosa de Cabal hasta la base militar del Cerro El Gualy. Este escenario nos sirvió para hablar de los "destinos silenciosos" en los que se han filmado películas como El Páramo o Memoria. Nuestra invitada es Quinaya Qumir, miembro del equipo de la Falla y una de las investigadoras de la guía. Para consultar la Guía entra a este enlace: https://lafalla.co/rodandoporeleje/Este contenido llega a vos gracias a: El Patrocinio de La Falla Destino Fílmico Nuestra productora Gente queLa producción ejecutiva de Lemaitre ConsultoresEl amor y confianza de nuestros amigos en Patreon (Nataly Valdivieso, Hamilton Casas, Juliana Núñez, Diana Piñeres). Apóyanos como ellos desde 1 dólar.Si quieres pautar en nuestros episodios, patrocinar nuestro proyecto y todos sus productos como  #ElNoti semanal o producir tu pocdast no dudes en escribirnos a info@gentequehacecine.com Nuestra web: https://gentequehacecine.com/ 

Nálgast má þáttinn í heild sinni inn á; https://solvitryggva.is/ Ríkharð Óskar Guðnason hefur starfað við fjölmiðla í meira en 20 ár og ástríða hans fyrir íþróttum og útvarpi hefur hrifið fólk með í áraraðir. Í þættinum ræða Sölvi og Rikki um feril Rikka, fjölmiðla, einlægni, erfiðleika við barneignir, sorgina eftir föðurmissinn og margt fleira. Þátturinn er í boði; Caveman - https://www.caveman.global/ Nings - https://nings.is/ Myntkaup - https://myntkaup.is/ Biofit - https://biofit.is/ Exoquad - https://www.exoquad.is

Ásmundur Guðni Haraldsson er maður margra hatta. Hann er aðstoðarskólameistari í Brekkubæjarskóla á Akranesi, aðstoðarþjálfari kvennalandsliðsins í knattspyrnu og landsliðsþjálfari Reitaboltalandsliðsins.Við Ási settumst niður og spjölluðum um væntanlegt Evrópumót, hvers vegna honum finnst svo gefandi að starfa með kvennalandsliðinu, liði sem hann hefur unnið með í yfir 100 landsleikjum og fórum yfir ferilinn frá því Guðjón Þórðar og Luka Luka Kostic gáfu honum sénsinn í KR.Ási sagði mér hvernig hann starfaði sem yfirþjálfari yngri flokka Gróttu og Stjörnunnar og við ræddum að sjálfsögðu það afrek sem hann náði er hann fór með Gróttu úr neðstu deild í þá næst efstu. Auðvitað fórum við svo yfir tímann hjá FH!Síðast, en alls ekki síst, fórum við djúpt ofan í reitaboltafræðin. Hvað gerist til dæmis ef þú klobbar tvo leikmenn í einni snertingu? Það er e.t.v. kominn tími til að gefa út nýtt myndband frá reitaboltasambandinu.Njótið

Það eru níu dagar í fyrsta leik Íslands á Evrópumótinu í Sviss. Guðmundur Aðalsteinn, Magnús Haukur Harðarson og Óskar Smári Haraldsson hita vel upp fyrir Evrópumótið í þætti dagsins af Uppbótartímanum. Hvernig eru andstæðingar Íslands og hverjar eiga vonir okkar og væntingar að vera? Einnig er aðeins talað um Bestu deildina fyrir langa EM-pásu sem er framundan.

Learn the story of Guðmundur of Keldur, a farmer who vanished every Christmas Eve and returned as if nothing had happened… Until one day, someone followed him!  This episode unearths a haunting folktale from North Iceland, where archaeological ruins whisper of pagan graves and mysterious forces still linger in the surrounding mountains... Like what you hear?  Give us 5 Stars!  And follow for more... Checkout our website: Eerie Iceland  Follow us on: Instagram  Find our page on: Facebook  Email us: hello@eerieiceland.com Sources & Extras: Source 1 Source 2 Source 3 Source 4 Source 5 Episode & Editing By: Ann Irene Peters (Iceland Wedding Planner)

LAUDES SÁBADO DE LA XI SEMANA DEL TIEMPO ORDINARIO(Oración de la mañana) - IV Salterio*Link de apoyo al canal al final del escrito*INVOCACIÓN INICIALV. Señor abre mis labiosR. Y mi boca proclamará tu alabanzaINVITATORIOAnt. Escuchemos la voz del Señor y entremos en su descanso.SALMODIASalmo 91 - Ant.Es bueno tocar para tu nombre, oh Altísimo, y proclamar por la mañana tu misericordia.Cántico - Ant. Os daré un corazón nuevo y os infundiré un espíritu nuevo.Salmo 8 - Ant. De la boca de los niños de pecho, Señor, has sacado una alabanzaCÁNTICO EVANGÉLICOAnt. Guía nuestros pasos, Dios de Israel, por el camino de la paz.Cántico de Zacarías. EL MESÍAS Y SU PRECURSOR      Lc 1, 68-79Bendito sea el Señor, Dios de Israel,porque ha visitado y redimido a su pueblo.suscitándonos una fuerza de salvaciónen la casa de David, su siervo,según lo había predicho desde antiguopor boca de sus santos profetas:Es la salvación que nos libra de nuestros enemigosy de la mano de todos los que nos odian;ha realizado así la misericordia que tuvo con nuestros padres,recordando su santa alianzay el juramento que juró a nuestro padre Abraham.Para concedernos que, libres de temor,arrancados de la mano de los enemigos,le sirvamos con santidad y justicia,en su presencia, todos nuestros días.Y a ti, niño, te llamarán Profeta del Altísimo,porque irás delante del Señora preparar sus caminos,anunciando a su pueblo la salvación,el perdón de sus pecados.Por la entrañable misericordia de nuestro Dios,nos visitará el sol que nace de lo alto,para iluminar a los que viven en tinieblay en sombra de muerte,para guiar nuestros pasospor el camino de la paz.Gloria al Padre, y al Hijo, y al Espíritu Santo.Como era en el principio, ahora y siempre, por los siglos de los siglos. Amén.PRECES“Escúchanos, Señor. ”Conclusion. El Señor nos bendiga, nos guarde de todo mal y nos lleve a la vida eterna.R. Amén.(364)

Daydreaming of registering for a marathon or in the thick of training? Wherever you fall on the marathon-spectrum (including “no way, no how!”), you'll enjoy this episode. Hosts Sarah Bowen Shea and Coach Liz Waterstraat talk to four “regular” runners about their debut marathon pursuits. They cover topics such as: -their marathon motivations; -the satisfaction of setting and striving toward a goal; -how the run/walk method makes 26.2 attainable; -the “delicious pain” that comes with covering the miles; and, -the mountain of laundry generated during training! Before the first marathoner joins around 10:38, the hosts share about their first marathons—and Chicagoland's “garbage hills!” Register for our Lake Placid retreat.  When you shop our sponsors, you help AMR. We appreciate your—and their—support! GU for it: Get 20% off with code AMR2520 at GUenergy.com thru 6/30/25  Use code INF-AMR to get a gift card good for your next purchase at Selkirk.com  Get 20% off, plus free shipping, on allIQBAR products by texting AMR to 64-000 Learn more about your ad choices. Visit megaphone.fm/adchoices

www.patreon.com/skodanabraedurStyrktaraðilar þáttarins: Myntkaup, Silkisvefn, World Class, Gæði & Takk takk (15% afsláttur á takktakk.is með kóðanum SB15).Það sem snert er á: Íslenskt sjálfstæði, menntakerfið, stjórnarskráin, Napóleon, Bitcoin, Jordan Peterson, bókun 35, Hans Herman-Hoppe, 19. öld, afnám velferðarkerfis og Guð.